• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cancer risk with GLP-1RA: what can real-world data really tell us?胰高血糖素样肽-1受体激动剂（GLP-1RA）与癌症风险：真实世界数据究竟能告诉我们什么？
Lancet Reg Health Eur. 2025 Jul 16;55:101383. doi: 10.1016/j.lanepe.2025.101383. eCollection 2025 Aug.
2
GLP-1RA Use and Thyroid Cancer Risk.胰高血糖素样肽-1受体激动剂的使用与甲状腺癌风险
JAMA Otolaryngol Head Neck Surg. 2025 Mar 1;151(3):243-252. doi: 10.1001/jamaoto.2024.4852.
3
Understanding and Overcoming Negative Attitudes That Hinder Adoption of Reablement in Dementia Care: An Explorative Qualitative Study.理解并克服阻碍痴呆症护理中采用康复护理的消极态度：一项探索性定性研究
J Multidiscip Healthc. 2025 Jun 12;18:3411-3422. doi: 10.2147/JMDH.S522515. eCollection 2025.
4
Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management.使用胰高血糖素样肽-1受体激动剂进行体重管理的患者发生急性胰腺炎的预测因素。
Pancreatology. 2025 Aug;25(5):609-613. doi: 10.1016/j.pan.2025.06.018. Epub 2025 Jun 26.
5
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.关于新型基于胰高血糖素样肽-1受体激动剂（GLP-1RA）的减肥疗法的使用、临床及对比疗效和不良反应的真实世界证据。
Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.
6
Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies.胰高血糖素样肽-1受体激动剂与其他降糖药物对2型糖尿病患者心血管和肾脏的有效性：一项真实世界研究的系统评价和荟萃分析
Metabolites. 2022 Feb 15;12(2):183. doi: 10.3390/metabo12020183.
7
Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin.二甲双胍治疗的2型糖尿病患者使用胰高血糖素样肽-1受体激动剂与对照药物相比强化治疗的时机
Diabetes Ther. 2025 May 22. doi: 10.1007/s13300-025-01751-6.
8
The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.注射用胰高血糖素样肽-1（GLP-1）受体激动剂与口服二肽基肽酶-4（DPP-4）抑制剂和钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂的安慰剂反应：一项系统评价和荟萃分析。
Br J Clin Pharmacol. 2016 Jul;82(1):301-14. doi: 10.1111/bcp.12925. Epub 2016 Apr 22.
9
Self-Set Goals: Autistic Adults Facilitating Their Self-Determination Through Digitally Mediated Social Stories.自我设定目标：成年自闭症患者通过数字媒介社交故事促进自我决定
Autism Adulthood. 2025 Feb 5;7(1):25-38. doi: 10.1089/aut.2023.0063. eCollection 2025 Feb.
10
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.在真实世界的 2 型糖尿病患者中，GLP-1 受体激动剂与其他降糖药物的心血管安全性比较：一项全国范围内基于人群的队列研究。
Cardiovasc Diabetol. 2020 Jun 13;19(1):83. doi: 10.1186/s12933-020-01053-0.

本文引用的文献

1
2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health: A Report of the American College of Cardiology Solution Set Oversight Committee.《2025简明临床指南：美国心脏病学会关于优化心血管健康的医学体重管理专家共识声明：美国心脏病学会解决方案集监督委员会报告》
J Am Coll Cardiol. 2025 Aug 19;86(7):536-555. doi: 10.1016/j.jacc.2025.05.024. Epub 2025 Jun 20.
2
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.关于新型基于胰高血糖素样肽-1受体激动剂（GLP-1RA）的减肥疗法的使用、临床及对比疗效和不良反应的真实世界证据。
Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.
3
Trends in cause-specific mortality among people with type 2 and type 1 diabetes from 2002 to 2019: a Danish population-based study.2002年至2019年2型和1型糖尿病患者特定病因死亡率的趋势：一项基于丹麦人群的研究。
Lancet Reg Health Eur. 2024 Apr 26;41:100909. doi: 10.1016/j.lanepe.2024.100909. eCollection 2024 Jun.
4
Current and future state of pharmacological management of pediatric obesity.小儿肥胖症药物治疗的现状与未来发展态势
Int J Obes (Lond). 2025 Mar;49(3):388-396. doi: 10.1038/s41366-024-01465-y. Epub 2024 Feb 6.
5
Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.Meta 分析与 2 型糖尿病患者抗糖尿病药物处方相关的因素。
Eur J Clin Invest. 2023 Aug;53(8):e13997. doi: 10.1111/eci.13997. Epub 2023 Apr 10.
6
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.胰高血糖素样肽 1 受体激动剂：心血管获益及其作用机制。
Nat Rev Cardiol. 2023 Jul;20(7):463-474. doi: 10.1038/s41569-023-00849-3. Epub 2023 Mar 28.

Cancer risk with GLP-1RA: what can real-world data really tell us?

作者信息

Jessen Niels, Støvring Henrik

机构信息

Steno Diabetes Center Aarhus, Aarhus University Hospital, Palle Juul-Jensens Blvd. 11, 8200, Aarhus, Denmark.

Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000, Aarhus, Denmark.

出版信息

Lancet Reg Health Eur. 2025 Jul 16;55:101383. doi: 10.1016/j.lanepe.2025.101383. eCollection 2025 Aug.

DOI:10.1016/j.lanepe.2025.101383
PMID:40704041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12284705/
Abstract
摘要